Company Overview
Company Type: Public Company
Website: www.intelgenx.com
Number of Employees: 50
Ticker: IGXT (OTCPK)
Year Founded: 1999


Business Description
IntelGenx Technologies Corp., a drug delivery company, focuses on the development and manufacturing of novel oral thin film products for the pharmaceutical market. It offers INT0008/2008, a Rizatriptan oral film product for the treatment of migraine; INT0046/2018 and INT0055/2021 are for adult use; INT0007/2006, an oral film product for treatment of erectile dysfunction; INT0043/2015, an oral film containing montelukast for treatment of Alzheimer; INT0027/2011 to treat opioid addition; INT0010/2006 for treatment of neuropathic pain and nausea in cancer patients undergoing chemotherapy; INT0036/2013, an oral film product for schizophrenia or bipolar 1 disorder; and INT0048/2020 for animal health. It is also developing INT0039/2013, INT0053/2020, and INT0054/2020. The company has licensing, development, and supply agreement with Tilray, Inc.; and development agreement with Cynapsus Therapeutics Inc. IntelGenx Technologies Corp. was incorporated in 1999 and is headquartered in Montreal, Canada.

Financial Information (Currency: CAD, in mm) 
Total Revenue
0.8
Market Capitalization
30.9
TEV/Total Revenue
58.4x
EBITDA
(12.6)
Total Enterprise Value
48.5
TEV/EBITDA
NM
EBIT
(13.7)
Cash & ST Invst.
1.7
P/Diluted EPS Before Extra
NM
Net Income
(15.2)
Total Debt
19.3
Price/Tang BV
NM
Capital Expenditure
(0.4)
Total Assets
10.6
Total Debt/EBITDA
NM
Currency in CAD in mm, LTM as of Jun-30-2023 TEV and Market Cap are calculated using a close price as of Oct-10-2023


Estimates Snapshot (Current Fiscal Year End: Dec-31-2021)




Non-Periodic Estimates

Recommendation
Outperform (2.00)


Key Professionals
Name
Title
Gorham, Dwight 
Chief Executive Officer
Godin, André 
President & CFO
Kilmer, Stephen 
Investor Relations Officer
Kenny, Tommy 
Senior VP & General Counsel
Paiement, Nadine 
Vice-Chair of Scientific Advisory Board and VP of Research & Development - IntelGenx Corp
Zerbe, Ingrid 
Corporate Secretary

Key Board Members
Name
Title
Zerbe, Horst G.
Chairman & Chairman of Scientific Advisory Board
Paiement, Nadine 
Vice-Chair of Scientific Advisory Board and VP of Research & Development - IntelGenx Corp
Melchers, Bernd J.
Independent Director
Nawacki, Mark H.
Independent Director
Aigner, Ludwig
Member of Scientific Advisory Board
Gauthier, Serge 
Member of Scientific Advisory Board
Greenberg, Barry D.
Member of Scientific Advisory Board
Mayr, Clemens 
Director
Rao, Srinivas G.
Director
Stegert, Frank 
Director
Trzcinska, Monika 
Independent Director


Primary Industry Classification
Pharmaceuticals


Primary Office Location
6420 Abrams Ville Saint Laurent | Montreal, QC | H4S 1Y2 | Canada
Phone: 514-331-7440   Fax: 514-331-0436

Current and Pending Investors
Acker Finley Asset Management Inc., Alpha Capital Anstalt, AlphaNorth Asset Management, ATAI Life Sciences AG, Cantone Asset Management, LLC, CBH Compagnie Bancaire Helvétique SA, Asset Management Arm, Endeavor Asset Management L.P., Leede Jones Gable Inc., Next Edge Capital Corp., Northwest & Ethical Investments L.P., Tilray Brands, Inc. (NasdaqGS:TLRY)

Prior Investors
BluMont Capital Corporation, Horizons Northern Rivers Fund LP, Northern Rivers Capital Management, Inc., Northern Rivers Innovation Fund LP, Northern Rivers Innovation RSP Fund, Northwest Funds - NEI Northwest Macro Canadian Equity Fund, Roadmap Capital Inc., Tilray, Inc. prior to merger with Aphria Inc.

Stock Quote and Chart (Currency: CAD)
Last  (Delayed)
 0.19
Market Cap (mm)
34.0
Open
 0.19
Shares Out. (mm)
174.7
Previous Close
 0.19
Float %
74.6%
Change on Day
0.02
Shares Sold Short (mm)
0.0
Change % on Day
10.0%
Dividend Yield %
-
Day High/Low
 0.19/ 0.19
Diluted EPS Excl. Extra Items
(0.09)
52 wk High/Low
 0.37/ 0.14
P/Diluted EPS Before Extra
NM
Volume (mm)
0.09
Avg 3M Dly Vlm (mm)
0.06
Beta 5Y
2.36


 
Delayed Quote** | Last Updated on Oct-11-2023 12:00 AM (GMT-5)
OTCPK:IGXT - Common Stock


Company Notes
No Company Notes exist.


Strategy Notes
No Strategy Notes exist.


Current and Pending Subsidiaries / Investments
Company Name
Business Description
Geography
Primary Industry
LTM Total Rev.($mm)
LFQ Total Assets ($mm)
LFQ Total Debt ($mm)
CPI-300
As of May 7, 2010, CPI-300 was acquired by IntelGenx Technologies Corp. CPI-300 comprises an antidepressant drug CPI-300. CPI-300 consists of an ingredient Bupropion hydrochloride ("HCl").

United States and Canada
Pharmaceuticals
-
-
-
Cannasat Therapeutics, Inc., Relivar License
As of December 31, 2010, Relivar License of Cannasat Therapeutics, Inc. was acquired by IntelGenx Technologies Corp.. Cannasat Therapeutics, Inc., Relivar License comprises an exclusive worldwide license to develop and commercialize Relivar, a novel formulation of dronabinol, utilizing IntelGenx’s proprietary mucoadhesive AdVersa technology, for the treatment of various diseases including neuropathic pain. Cannasat Therapeutics Inc. is based in Toronto, Canada.

United States and Canada
Pharmaceuticals
-
-
-
Big Flash Corp.
As of April 28, 2006, Big Flash Corp. was acquired by IntelGenx Corp. Big Flash Corporation, through its subsidiary, Intelgenx Corp., focuses on the development of oral controlled-release products for the generic pharmaceutical market, as well as mucosal delivery systems. The company uses two proprietary drug delivery platform technologies to develop products, Tri-Layer Tablet technology, which allows for the development of oral controlled release products; and Quick Release Wafer technology for the rapid delivery of pharmaceutically active substances to the oral cavity. Its product portfolio comprises INT0001/2004, a generic product involving trilayer technology for the treatment of CHF and hypertension; INT0003/2005, which is intended for the treatment smoking cessation; INT0004/2006, for use as an antidepressant; INT0005/2005, a bilayer tablet containing a fixed-dose combination of a nonsteroidal antiinflammatory drug and a synthetic prostaglandin for the treatment of osteoarthritis; INT0006/2005, a prenatal vitamin supplement product involving the company's proprietary manufacturing technology; and INT0007/2006, a wafer product based on proprietary edible film technology that is intended for the treatment of erectile dysfunction. Big Flash Corporation has a strategic partnership with Keata Pharma, Inc. The company was founded in 2003 and is based in Ville Saint-Laurent, Canada.

United States and Canada
Biotechnology
0.00
1.00
0.00
IntelGenx Corp.
IntelGenx Corp., a drug delivery company, focuses on the development of novel oral immediate-release and controlled-release products for the pharmaceutical market. The company develops its products based on three delivery platform technologies, including VersaFilm, an oral film technology; VersaTab, a multilayer tablet technology; and AdVersa, a mucoadhesive tablet technology. Its products comprise INT0001/2004, an anti-hypertension drug; INT0004/2006, an antidepressant; INT0007/2006 for the treatment of erectile dysfunction; INT0008/2007 for migraine; INT0010/2006 for the treatment of neuropathic pain and nausea in cancer patients; INT0027/2011 to treat opioid dependence; INT0036/2013 for schizophrenia; and INT0043/2015 to treat Alzheimer’s disease. It is also developing INT0037/2013, INT0039/2013, INT0040/2014, INT0042/2015, INT0043/2015, and INT0044/2016. The company has co-development and commercialization agreements with RedHill Biopharma Ltd., Par Pharmaceutical Companies, Inc., and Endo Ventures Ltd.; licensing, development, and supply agreement with Chemo Group; and development agreement with Cynapsus Therapeutics Inc. IntelGenx Corp. is based in Saint-Laurent, Canada. IntelGenx Corp. operates as a subsidiary of IntelGenx Technologies Corp.

United States and Canada
Pharmaceuticals
-
-
-


Last 5 Transactions
Announced Date
Closed Date
Transaction Type
Role
Target
Buyer/Investors
Sellers
Size($mm)
Aug-31-2023
-
Private Placement
Target
IntelGenx Technologies Corp. (OTCPK:IGXT)
ATAI Life Sciences AG

6.97
Apr-10-2023
-
Shelf Registration
Target
IntelGenx Technologies Corp. (OTCPK:IGXT)


1.04
Mar-21-2023
Mar-21-2023
Private Placement
Target
IntelGenx Technologies Corp. (OTCPK:IGXT)


0.73
Jul-27-2021
Aug-05-2021
Private Placement
Target
IntelGenx Technologies Corp. (OTCPK:IGXT)


2.10
Mar-14-2021
Sep-30-2021
Public Offering
Target
IntelGenx Technologies Corp. (OTCPK:IGXT)


12.35
* denotes that the relationship is proprietary


Last 5 Key Developments
Date
Event Type
Headline
Sep-26-2023
Product-Related Announcements
Gensco® Pharma and Intelgenx Announces Rizafilm Commercialization Update in the United States
Sep-21-2023
Client Announcements
Intelgenx Corp. Receives the First Purchase Order for Rizafilm
Sep-19-2023
Product-Related Announcements
IntelGenx Corp. Provides Regulatory Update for Xiromed-Partnered Development Candidate, Buprenorphine Buccal Film
Aug-31-2023
Private Placements
IntelGenx Technologies Corp. announced that it expects to receive CAD 9.43492 million in funding from ATAI Life Sciences AG
Aug-22-2023
Product-Related Announcements
Intelgenx Technologies Corp. Completes Enrollment for `Buena' Montelukast Versafilm® Phase 2A Clinical Trial in Patients with Mild to Moderate Alzheimer's Disease

Competitors
Aquestive Therapeutics, Inc. (NasdaqGM:AQST), Arx Pharma Limited, Avenir Wellness Solutions, Inc. (OTCPK:AVRW), BioDelivery Sciences International, Inc. (NasdaqGS:BDSI), Collegium Pharmaceutical, Inc. (NasdaqGS:COLL), Lonza Group AG (SWX:LONN), LTS Lohmann Therapy Systems Corporation, tesa Labtec GmbH


Advisors
Most Recent Auditor
Richter LLP
Private Placement Advisors
Bolder Investment Partners, Ltd., Borden Ladner Gervais LLP, Cantone Research, Inc., Cantone Research, Inc., Investment Banking Arm, Carter Securities, LLC, Dorsey & Whitney LLP, Echelon Wealth Partners Inc., Hodgson Russ LLP, Paradigm Capital Inc., Rodman & Renshaw, LLC, Union Securities Ltd.
Public Offering Advisors
Borden Ladner Gervais LLP, Dorsey & Whitney LLP, Echelon Wealth Partners Inc., H.C. Wainwright & Co., LLC, McCarthy Tétrault LLP, Richter LLP


Most Recent Auditor
RSM Richter LLP


Last 10 Investment Research Documents
Contributor
Analyst
Date/Time
Company
Headline
Type
Pages
S&P Global Compustat

Oct 05, 2023 03:44 AM
IGXT
Intelgenx Technologies Corp 2023_10_05
Reports
14
ValuEngine, Inc.

Oct 02, 2023 06:19 AM
IGXT
ValuEngine - Toronto Quantitative Stock Report for IGX
Reports
5
MarketLine

Sep 20, 2023 06:01 AM
IGXT
IntelGenx Technologies Corp
Reports
28
SADIF-Investment Analytics S.A.
SADIF-Investment Analytics Research Team
Sep 19, 2023 06:00 PM
IGXT
Rating Update for Intelgenx Technologies Corp
EPS Estimates*
3
S&P Global Compustat

Sep 07, 2023 03:27 AM
IGXT
Intelgenx Technologies Corp 2023_09_07
Reports
14
SADIF-Investment Analytics S.A.
SADIF-Investment Analytics Research Team
Aug 24, 2023 06:00 PM
IGXT
Rating Update for Intelgenx Technologies Corp
EPS Estimates*
3
S&P Global Compustat

Jul 06, 2023 03:00 AM
IGXT
Intelgenx Technologies Corp 2023_07_06
Reports
14
SADIF-Investment Analytics S.A.
SADIF-Investment Analytics Research Team
Jun 21, 2023 06:00 PM
IGXT
Rating Update for Intelgenx Technologies Corp
EPS Estimates*
3
S&P Global Compustat

Jun 01, 2023 03:46 AM
IGXT
Intelgenx Technologies Corp 2023_06_01
Reports
14
Wright Investors' Service Inc.

May 23, 2023 01:45 AM
IGXT
Flow of Funds Report for IntelGenx Technologies Corp. - prepared by Wright Investors Service
Notes
67


Ownership Summary

            Top Holders 
Holders by Type
Holder

Common Stock Equivalent Held

% of Total Shares Outstanding

Market Value (CAD in mm)

Position Date


Atai Life Sciences N.V.

37,300,000

21.36

7.1

Aug-31-2023


Zerbe, Ingrid 

5,843,459

3.35

1.1

Mar-28-2023


Zerbe Ph.D., Horst G.

368,064

0.21

0.1

Apr-13-2023


Godin C.A., CPA, CA, CPA, André 

308,399

0.18

0.1

Apr-04-2023


Boudreau Sr., PC, Q.C., QC, J. Bernard

175,000

0.10

0.0

Mar-28-2023


Kenny J.D., L.L.B., M.Sc., Tommy 

138,500

0.08

0.0

Apr-04-2023


Melchers B.A., BA, Bernd J.

120,000

0.07

0.0

Mar-28-2023


Matzen PH.D., Dana 

85,000

0.05

0.0

Jan-29-2023


Paiement, Nadine 

60,000

0.03

0.0

Mar-28-2023


Kalayajian CPA, Karen 

50,000

0.03

0.0

Apr-13-2023



 



Top Buyers
Buyers
Common Stock Equivalent Held
Change
Kalayajian CPA, Karen 
50,000
50,000

Top Sellers
Sellers
Common Stock Equivalent Held
Change
Zerbe Ph.D., Horst G.
368,064
(4,238,679)
Monetary Management Group Inc
0
(5,000)


S&P Global Ratings Credit Ratings
No S&P Global Ratings Credit Ratings data available. 


News Headlines
No News is currently available for the selected sources.


Company Coverage
This company is not on any Coverage List.

Products
Anti-migraine VersaFilm, CAT 320 (Future), Clinical Monitoring Services, Commercial Manufacturing Services, CPI-300, Hand Sanitizer (Future), INT0001/2004 (Future), INT0003/2005 (Future), INT0004/2006 (Future), INT0005/2005 (Future), INT0007/2006 (Future), INT0008/2007, INT0008/2008 (Future), INT0010/2006 (Future), INT0011/2007 (Future), INT0014/2008 (Future), INT0015/2008 (Future), INT0018/2008 (Future), INT0019/2009 (Future), INT0020/2010 (Future), INT0022 (Future), INT0024/2010 (Future), INT0025/2010 (Future), INT0026/2011 (Future), INT0027/2011 (Future), INT0028/2011 (Future), INT0029/2011 (Future), INT0030/2011 (Future), INT0031/2012 (Future), INT0036/2012 (Future), INT0036/2013 (Future), INT0037/2013 (Future), INT0039/2013 (Future), INT0040/2013 (Future), INT0040/2014 (Future), INT0041/2015, INT0042/2015 (Future), INT0043/2015 (Future), INT0044/2016 (Future), INT0045/2018 (Future), INT0046/2018 (Future), INT0052/2020 (Future), INT0053/2020 (Future), INT0054/2020 (Future), INT0055/2021, INT007 (Future), Licensing of Forfivo XL, Loxapine VersaFilm (Future), Montelukast VersaFilm (Future), Opioid dependence VersaFilm (Future), Pharmaceutical Research and Development Services, Regulatory Support Services, Rizafilm (Future), RIZAPORT, RIZAPORT VersaFilm (Future), Suboxone Sublingual Film (Future), Tech Transfer and Manufacturing Scale-up Services, VetaFilm


Upcoming Events
Date/Time
Type
Nov-14-2023
Estimated Earnings Release Date (S&P Global Derived)
Nov-28-2023
Shareholder/Analyst Calls
Nov-28-2023
Special/Extraordinary Shareholders Meeting
* Future Events are subject to change.


Recent Major Filings

Key Filings
Filed On
Period Date
Company Name
Source
Form Type
Size
Oct-06-2023
-
IntelGenx Technologies Corp. (OTCPK:IGXT)
SEDAR
Management Proxy Materials
265 KB
Oct-06-2023
Nov-28-2023
IntelGenx Technologies Corp. (OTCPK:IGXT)
SEC
PRE 14A
182 KB
Sep-21-2023
-
IntelGenx Technologies Corp. (OTCPK:IGXT)
SEDAR
News Releases
24 KB
Sep-19-2023
-
IntelGenx Technologies Corp. (OTCPK:IGXT)
SEDAR
News Releases
22 KB
Sep-08-2023
-
IntelGenx Technologies Corp. (OTCPK:IGXT)
SEDAR
Material Change Report
138 KB
Sep-08-2023
-
IntelGenx Technologies Corp. (OTCPK:IGXT)
SEDAR
Material Change Report
88 KB
Sep-07-2023
-
IntelGenx Technologies Corp. (OTCPK:IGXT)
SEDAR
Notice of the Meeting and Record Date
164 KB
Sep-05-2023
-
IntelGenx Technologies Corp. (OTCPK:IGXT)
SEDAR
Securities Acquisition Filings (Early Warning)
368 KB
Aug-31-2023
Aug-31-2023
IntelGenx Technologies Corp. (OTCPK:IGXT)
SEC
8-K (1.01, 2.03, 3.02, 9.01)
517 KB
Aug-31-2023
-
IntelGenx Technologies Corp. (OTCPK:IGXT)
SEDAR
Material Change Report
510 KB


Insider Trades
Holder Name
Trade Date Range
Security Type
Transacted Shares
Transaction Value Range (CAD)
Transaction Type
% Change
Source
Zerbe Ph.D., Horst G. (Chairman & Chairman of Scientific Advisory Board)
Sep-30-2022
Common Shares
19,000
3,232
Open Market Acquisition
5.44
Form 4
-
Sep-30-2022
Common Shares
5,000
870
Open Market Acquisition
-
Form 4
-
Sep-30-2022
Common Shares
14,000
2,361
Open Market Acquisition
-
Form 4
Godin C.A., CPA, CA, CPA, André  (President & CFO)
Sep-29-2022
Common Shares
5,000
843
Open Market Acquisition
1.65
Form 4
Godin C.A., CPA, CA, CPA, André  (President & CFO)
Sep-28-2022
Common Shares
9,000
1,653
Private Acquisition
3.06
Form 4
Godin C.A., CPA, CA, CPA, André  (President & CFO)
Sep-27-2022
Common Shares
1,000
178
Open Market Acquisition
0.33
Form 4
Kenny J.D., L.L.B., M.Sc., Tommy  (Senior VP & General Counsel)
Sep-26-2022
Common Shares
19,000
3,489
Open Market Acquisition
15.90
Form 4
Excluding Automatic Transactions
Key Board Members Details
Name
Title
Phone
Fax
Email
Zerbe, Horst G.
Chairman & Chairman of Scientific Advisory Board
(514) 331-7440
514-331-0436
horst@IntelGenx.com
Paiement, Nadine 
Vice-Chair of Scientific Advisory Board and VP of Research & Development - IntelGenx Corp
514-331-7440
514-331-0436

Melchers, Bernd J.
Independent Director
514-331-7440
514-331-0436

Nawacki, Mark H.
Independent Director
514-331-7440
514-331-0436

Aigner, Ludwig
Member of Scientific Advisory Board
514-331-7440
514-331-0436
-
Gauthier, Serge 
Member of Scientific Advisory Board
514-331-7440
514-331-0436
serge.gauthier@mcgill.ca
Greenberg, Barry D.
Member of Scientific Advisory Board
514-331-7440
514-331-0436

Mayr, Clemens 
Director
(514) 397-4258
514-331-0436
cmayr@mccarthy.ca
Rao, Srinivas G.
Director
514-331-7440
514-331-0436

Stegert, Frank 
Director
514-331-7440
514-331-0436

Trzcinska, Monika 
Independent Director
514-331-7440
514-331-0436

* denotes that the relationship is proprietary

Key Executives and Professionals Details
Name
Title
Phone
Fax
Email
Gorham, Dwight 
Chief Executive Officer
514-331-7440
514-331-0436

Godin, André 
President & CFO
(514) 331-7440x203
514-331-0436
andre@intelgenx.com
Kilmer, Stephen 
Investor Relations Officer
514 331-7440x232
514-331-0436
stephen@intelgenx.com
Kenny, Tommy 
Senior VP & General Counsel
514-331-7440
514-331-0436

Paiement, Nadine 
Vice-Chair of Scientific Advisory Board and VP of Research & Development - IntelGenx Corp
514-331-7440
514-331-0436

Zerbe, Ingrid 
Corporate Secretary
514-331-7440
514-331-0436
Ingrid@intelgenx.com
* denotes that the relationship is proprietary

Historical Equity Pricing Data supplied by Interactive Data Pricing and Reference Data LLC 
S&P Credit Ratings and Research provided by 
No content (including ratings, credit-related analyses and data, valuations, model, software or other application or output therefrom) or any part thereof (Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior written permission of S&P Global Market Intelligence or its affiliates (collectively, S&P Global). The Content shall not be used for any unlawful or unauthorized purposes. S&P Global and any third-party providers, as well as their directors, officers, shareholders, employees or agents (collectively S&P Global Parties) do not guarantee the accuracy, completeness, timeliness or availability of the Content. S&P Global Parties are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, for the results obtained from the use of the Content, or for the security or maintenance of any data input by the user. The Content is provided on an "as is" basis. S&P GLOBAL PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS, SOFTWARE ERRORS OR DEFECTS, THAT THE CONTENT’S FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE WITH ANY SOFTWARE OR HARDWARE CONFIGURATION. In no event shall S&P Global Parties be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs or losses caused by negligence) in connection with any use of the Content even if advised of the possibility of such damages.

Credit-related and other analyses, including ratings, and statements in the Content are statements of opinion as of the date they are expressed and not statements of fact. S&P Global Market Intelligence’s opinions, analyses and rating acknowledgment decisions (described below) are not recommendations to purchase, hold, or sell any securities or to make any investment decisions, and do not address the suitability of any security. S&P Global Market Intelligence assumes no obligation to update the Content following publication in any form or format. The Content should not be relied on and is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment and other business decisions. S&P Global Market Intelligence does not act as a fiduciary or an investment advisor except where registered as such. While S&P Global Market Intelligence has obtained information from sources it believes to be reliable, S&P Global Market Intelligence does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives.

S&P Global keeps certain activities of its divisions separate from each other in order to preserve the independence and objectivity of their respective activities. As a result, certain divisions of S&P Global may have information that is not available to other S&P Global divisions. S&P Global has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process.

S&P Global Ratings does not contribute to or participate in the creation of credit scores generated by S&P Global Market Intelligence. Lowercase nomenclature is used to differentiate S&P Global Market Intelligence PD credit model scores from the credit ratings issued by S&P Global Ratings.

S&P Global may receive compensation for its ratings and certain analyses, normally from issuers or underwriters of securities or from obligors. S&P Global reserves the right to disseminate its opinions and analyses. S&P Global's public ratings and analyses are made available on its Web sites, www.standardandpoors.com (free of charge), and www.capitaliq.com (subscription), and may be distributed through other means, including via S&P Global publications and third-party redistributors. Additional information about our ratings fees is available at www.standardandpoors.com/usratingsfees.
Regulatory News Service data provided by 

**Intraday Quotes are delayed by at least 20 minutes.
